The most significantly identified enriched pathway were about the pancreatic cancer (P = 0.0011), which four target genes (CDC42, MAPK1, SMAD3, and CDK6) were predicted to be involved in. This evidence concerns the gene CDC42 and familial pancreatic carcinoma.